CA HEAL25 : Corporate Presentation September, 2022

September 2022

Disclaimer

FORWARD-LOOKING STATEMENTS

All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "potential," "seem," "seek," "future," "outlook," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics, projections of market opportunity and market share, our future results of operations and financial position, business strategy, the Platform, other products, test s, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of the management of LumiraDx Limited ("LumiraDx" or the "Company") and are not predictions of actual performance. These forward- looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and such differences may be material. Many actual events and circumstances are beyond the control of LumiraDx. These forward-looking statements are subject to a number of risks and uncertainties, including our ability to compete in the highly competitive markets in which we operate, and potential adverse effects of this competition; our ability to maintain revenues if our products and services do not achieve and maintain broad market acceptance, or if we are unable to keep pace or adapt to rapidly changing technology, evolving industry standards and changing regulatory environments; uncertainty, downturns and changes in the markets we serve; our expectations regarding the size of the POC market for the Platform, the size of the various addressable markets for certain tests and our ability to penetrate such markets by driving the conversion of healthcare providers' testing needs onto the Platform; our commercialization strategy, including our plans to initially focus our sales efforts on large healthcare systems, government organizations and national pharmacy chains that want to deploy comprehensive POC testing across their networks, our strategy on the commercialization of our current and future assays and our ability to launch and obtain regulatory approval for new tests; our ability to increase the installed base of our Instruments; our ability to repay or service our debt obligations and meet the financial covenants related to such debt obligations; our belief that we will be able to drive commercialization of the Platform through the launch of our SARS-CoV-2 antigen and SARS-CoV-2 antibody tests; the willingness of healthcare providers to use a POC sy stem over central lab systems and the rate of adoption of the Platform by healthcare providers and other users; the scalability and commercial viability of our manufacturing methods and processes, especially in light of the anticipated demand for the Platform and our minimum commitments to supply the Instrument and test strips in a timely fashion; our ability to maintain our current relationships, or enter into new relationships, with diagnostics or research and development companies, third party manufacturers and commercial distribution collaborators; our ability to effectively manage our anticipated growth; our ability to rapidly develop and commercialize diagnostics tests that are accurate and cost-effective; the timing, progress and results of our diagnostic tests, including statements regarding launch plans and commercialization plans for such tests, all which may be delayed by or halted due to a number of factors, including the impact of the COVID-19 pandemic and the end of the COVID-19 pandemic; the timing, scope or likelihood of regulatory submissions, filings, approvals, authorizations, certifications, clinical trials or clearances; the pricing, coverage and reimbursement of the Instrument and tests, if approved; our ability to enforce our intellectual property rights and to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; developments and projections relating to our competitors and our industry; our ability to attract, motivate and retain qualified employees, including members of our senior management team; the effects of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business or operations; social, economic, and labor instability in the countries in which we or the third parties with whom we engage operate, including any impact of the current conflict between Russia and Ukraine; our expectations regarding the time during which we will be an emerging growth company under the JOBS Act and a foreign private issuer; the future trading price of our common shares and impact of securities analysts' reports on these prices; our ability to fully derive anticipated benefits from existing or future acquisitions, joint ventures, investments or dispositions; exchange rate fluctuations and volatility in global currency markets; potential adverse tax consequences resulting from the international scope of our operations, corporate structure and financing structure; U.S. tax legislation enacted in 2017, which could materially adversely affect our financial condition, results of operations and cash flows; increased risks resulting from our international operations and expectations of future expansion of such operations; our ability to comply with various trade restrictions, such as sanctions and export controls, resulting from our international operations; government and agency demand for our products and services and our ability to comply with government contracting regulations; our ability to operate in a litigious environment; and those factors discussed under the header "Risk Factors" in the Annual Report on Form 20-F filed by LumiraDx with the Securities and Exchange Commission, or SEC, on April 13, 2022, in the Form 6-K filed by LumiraDx with the SEC on August 16, 2022, and in other filings made by LumiraDx with the SEC. If any of these risks materialize or LumiraDx's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that LumiraDx presently knows or that LumiraDx currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward- looking statements reflect LumiraDx's expectations, plans or forecasts of future events and views as of the date of this presentation. LumiraDx anticipates that subsequent events and developments will cause LumiraDx's asse ssments to change. However, while LumiraDx may elect to update these forward-looking statements at some point in the future, LumiraDx specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing LumiraDx's asse ssments as of any date subsequent to the date of thispresentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. LumiraDx hasno obligation to update thispresentation.

INDUSTRY AND MARKET DATA

This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. LumiraDx believes that these third-party sources and estimates are reliable, but has not independently verified them. LumiraDx's estimates of the potential market opportunities for its Platform include several key assumptions based on industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While LumiraDx believes that its own internal assumptions are reasonable, no independent source has verified such assumptions. The industry in which LumiraDx operatesissubject to a high degree of uncertainty and riskdue to a variety of important factorsthat could cause resultsto differ materially from those expressed in the estimatesmade by third partiesand by LumiraDx.

USE OF PROJECTIONS

This presentation contains projected financial information with respect to LumiraDx, including, but not limited to, estimated results for fiscal year 2025. Such projected financial information constitutes forward-looking information, and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial forecast information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. See "Forward-Looking Statements" paragraph above. Actual results may differ materially from the results contemplated by the financial forecast information contained in thispresentation, and the inclusion of such information in thispresentation should not be regarded asa representation by any person that the resultsreflected in such forecastswill be achieved.

2

Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide.

LumiraDx Today:

Transforming Community-based Healthcare

• Next Generation POC(1) Diagnostic Company
• Large Installed Base with Global Commercial Reach
• Manufacturing
  Designed for Scale
• Broad Menu and Pipeline

of Diagnostic Tests

• Experienced
  Management Team

Addressing the current limitations of legacy POC systems by bringing lab-comparable performance to the POC in minutes, a broad menu of tests on a single instrument, and a low cost of ownership

25,000 instruments shipped to 105 countries across primary care, pharmacy, hospital emergency departments, global health, and other settings

All current and future POC tests are developed on common strip design, enabling flexible, automated and low-cost manufacturing on a single line. Current manufacturing capacity of 28 million test strips per month

Regulatory clearance for 12 tests for use on our Platform, with global TAM of $5B+ (excluding COVID).(2) 50+ assays in three-year roadmap

Fourth POC company for founding team. Management team has a successful track record of diagnostic innovation and building / scaling companies in POC

(1) "POC" means point of care.	3
(2) Global Total Addressable Market ("TAM"): We estimate each test based on our current assumptions, including (a) the existing market sizes, (b) central lab market that could
move to POC; and (c) expansion of diagnostic testing.

Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide.

Leadership Team

Management Experience

Ron Zwanziger	Dave Scott, Ph.D.	Jerry McAleer, Ph.D.	Nigel Lindner, Ph.D.	(Founders)	(Founders)	(Founders)
CEO, Co-Founder,	Chief Technology Officer,	Chief Scientist,	Chief Innovation
Chairman and Director	Co-Founder and Director	Co-Founder and Director	Officer

Tom Quinlan		David Walton, D.M.S.		Peter Scheu		Veronique Ameye
General Manager,		Chief Commercial		President, North American		Executive Vice President
Health IT		Officer		Commercial Operations		and General Counsel

Dorian LeBlanc, C.P.A.	Pooja Pathak
CFO and Vice President,	Chief Product Officer
Global Operations

4

Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide.

Company & Market

Introduction

Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide.